专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20150037326A1 Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen 审中-公开
标题翻译：药物组合物，其包含聚合物载体载体复合物和抗原
公开(公告)号：US20150037326A1
公开(公告)日：2015-02-05
申请号：US14375392
申请日：2013-01-30
申请人： BAYER INNOVATION GMBH , CUREVAC GMBH , ICON GENETICS GMBH
发明人： John-Edward Butler-Ransohoff , Karl-Josef Kallen , Thomas Kramps , Victor Klimyuk , Franziska Jarczowski
IPC分类号： A61K47/36 , C07K16/18 , A61K39/395 , A61K39/39 , A61K39/00
CPC分类号： A61K47/36 , A61K39/0011 , A61K39/39 , A61K39/39558 , A61K47/643 , A61K47/645 , A61K47/646 , A61K2039/505 , A61K2039/55511 , A61K2039/55516 , A61K2039/55561 , A61K2039/572 , A61K2039/585 , A61K2039/6081 , C07K16/18 , C07K16/3061 , C07K16/4208 , C07K2317/13 , C07K2317/55 , C07K2317/76 , C12N15/8258 , C12N15/87 , C12N2770/00043 , C12N2770/40043
摘要： The present invention is directed to a pharmaceutical composition including (eg for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components and as a cargo at least one nucleic acid (molecule) and at least one antigen associated with a tumour or cancer disease selected from; an idiotype immunoglobulin (e.g. an idiotype antibody or an idiotype B cell receptor); or at least one idiotype T cell receptor, or in each case a fragment, variant and/or derivative thereof. The inventive pharmaceutical composition allows for efficient induction of an adaptive immune response directed against the idiotype immunoglobulin or T cell receptor, particularly of a Th1-shiftet immune response. The present invention furthermore provides kits or kits of parts comprising the components of the inventive pharmaceutical composition, as well as the use of the inventive pharmaceutical composition or the inventive kit as a vaccine, particularly in the therapy of a tumour or cancer disease such as lymphoma, particularly B cell or T cell lymphoma.
摘要翻译：本发明涉及包含（例如用作佐剂）聚合物载体货物复合物的药物组合物，其包含作为载体的由二硫键交联的阳离子组分形成的聚合物载体和作为货物的至少一种核酸（分子）和与选自以下的肿瘤或癌症疾病相关的至少一种抗原; 独特型免疫球蛋白（例如独特型抗体或独特型B细胞受体）; 或至少一种独特型T细胞受体，或在每种情况下为其片段，变体和/或衍生物。本发明的药物组合物允许有效诱导针对独特型免疫球蛋白或T细胞受体，特别是Th1移位免疫应答的适应性免疫应答。本发明还提供了包含本发明药物组合物组分的试剂盒或试剂盒，以及本发明的药物组合物或本发明试剂盒作为疫苗的用途，特别是用于治疗肿瘤或癌症疾病例如淋巴瘤，特别是B细胞或T细胞淋巴瘤。

52. 发明授权

US09890391B2 RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop 有权
公开(公告)号：US09890391B2
公开(公告)日：2018-02-13
申请号：US14388220
申请日：2013-03-27
申请人： CureVac GmbH
发明人： Andreas Thess , Karl-Josef Kallen
IPC分类号： C12N15/00 , C12N15/85 , C12N15/67 , C12N15/88 , A61K48/00
CPC分类号： C12N15/85 , A61K48/00 , C12N15/67 , C12N15/88 , C12N2830/50
摘要： The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′UTR element comprising a nucleic acid sequence which is derived from the 3′UTR of an albumin gene or from a variant of the 3′UTR of an albumin gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′UTR element comprising a nucleic acid sequence which is derived from the 3′UTR of an albumin gene or from a variant of the 3′UTR of an albumin gene for the stabilization and/or prolongation of protein expression from a nucleic acid sequence comprising such 3′UTR element.

53. 发明授权

US09683233B2 Artificial nucleic acid molecules for improved protein or peptide expression 有权
公开(公告)号：US09683233B2
公开(公告)日：2017-06-20
申请号：US14388226
申请日：2013-03-27
申请人： CureVac GmbH
发明人： Andreas Thess
IPC分类号： C12N15/113 , C12Q1/68 , C12N15/68 , C12N15/85 , C12N15/67 , A61K48/00
CPC分类号： C12N15/113 , A61K39/00 , A61K48/00 , A61K48/0008 , A61K2039/5156 , A61K2039/5256 , A61K2039/53 , C12N15/67 , C12N15/85 , C12N2310/531 , C12N2320/52 , C12N2840/105
摘要： The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3′UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.

54. 发明授权

US09314535B2 Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids 有权
标题翻译：用于转染核酸的二硫键连接的聚乙二醇/肽缀合物
公开(公告)号：US09314535B2
公开(公告)日：2016-04-19
申请号：US14195864
申请日：2014-03-04
申请人： CureVac GmbH
发明人： Patrick Baumhof , Thomas Schlake
IPC分类号： A61K38/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , A61K47/48
CPC分类号： A61K48/0041 , A61K47/60 , A61K47/6455
摘要： The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.
摘要翻译：本发明涉及根据通式（I）的本发明的聚合物载体分子及其变体，其允许核酸在体内和体外有效转染细胞，由核酸形成的聚合载体载体复合物和本发明的聚合物载体分子，而且还涉及本发明的聚合物载体分子和本发明的聚合物载体载体复合物的制备方法。本发明还提供了本发明的聚合物载体分子和本发明的聚合物载体载体复合物作为药物，用于治疗各种疾病和制备用于治疗这些疾病的药物组合物的应用和应用的方法。

55. 发明申请

US20150218554A1 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PEPTIDE EXPRESSION 有权
标题翻译：用于改善蛋白质或肽表达的人造核酸分子
公开(公告)号：US20150218554A1
公开(公告)日：2015-08-06
申请号：US14388226
申请日：2013-03-27
申请人： CureVac GmbH
发明人： Andreas Thess
IPC分类号： C12N15/113 , C12N15/85
CPC分类号： C12N15/113 , A61K39/00 , A61K48/00 , A61K48/0008 , A61K2039/5156 , A61K2039/5256 , A61K2039/53 , C12N15/67 , C12N15/85 , C12N2310/531 , C12N2320/52 , C12N2840/105
摘要： The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3′UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
摘要翻译：本发明涉及包含至少一个5'UTR元件的人源核酸分子，其衍生自TOP基因，至少一个开放阅读框，优选至少一个组蛋白茎环。任选地，人造核酸分子可以进一步包含，例如， poly（A）序列，poyladenylation信号和/或3'UTR。本发明还涉及这种人工核酸分子在基因治疗和/或基因疫苗接种中的用途。

56. 发明申请

US20150118183A1 NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION 审中-公开
标题翻译：负责充电的核酸包含免疫复合物
公开(公告)号：US20150118183A1
公开(公告)日：2015-04-30
申请号：US14375364
申请日：2013-01-31
申请人： CUREVAC GMBH
发明人： Patrick Baumhof
IPC分类号： A61K39/39 , A61K39/145
CPC分类号： A61K39/39 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K47/543 , A61K47/59 , A61K47/645 , A61K47/646 , A61K2039/55561 , A61K2039/57 , A61K2039/6031 , C12N2760/16134 , Y02A50/386 , Y02A50/416 , Y02A50/487 , Y02A50/489
摘要： The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.
摘要翻译：本发明涉及包含（例如，用作佐剂）的（带负电荷的）核酸的药物组合物，其包含作为载体的阳离子或多阳离子化合物（例如肽，蛋白质或聚合物）和作为货物的至少一种核酸（分子）和至少一种选自与感染性疾病相关的病原体的抗原的抗原; 与过敏或过敏性疾病相关的抗原; 与自身免疫性疾病相关的抗原; 或与癌症或肿瘤疾病相关的抗原，或在每种情况下都是所述抗原的片段，变体和/或衍生物。药物组合物允许有效诱导针对所述抗原的适应性免疫应答。本发明还提供试剂盒，以及药物组合物或试剂盒作为疫苗的用途，特别是用于治疗感染性疾病，过敏反应，自身免疫性疾病和肿瘤或癌症疾病。

57. 发明申请

US20130251742A1 COMPOSITION FOR TREATING PROSTATE CANCER (PCa) 审中-公开
标题翻译：治疗前列腺癌（PCa）的组合物
公开(公告)号：US20130251742A1
公开(公告)日：2013-09-26
申请号：US13759542
申请日：2013-02-05
申请人： CUREVAC GMBH
发明人： Jochen Probst , Ingmar Hoerr , Thomas Lander
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K39/00 , A61K39/39 , A61K2039/53 , A61K2039/55516 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
摘要翻译：本发明涉及包含至少一种RNA（优选mRNA）的活性（免疫刺激性）组合物，其编码至少两种（优选不同的）能够在哺乳动物中引发（适应性）免疫应答的抗原，其中所述抗原选自组由PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原）和STEAP（前列腺的六跨膜上皮抗原）组成。本发明还涉及包含所述活性（免疫刺激）组合物的疫苗，以及所述活性（免疫刺激性）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的用途治疗前列腺癌（PCa），优选新辅助和/或激素难治性前列腺癌，以及与之相关的疾病或病症。最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。

58. 发明申请

US20130202645A1 COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) 有权
标题翻译：用于治疗肺癌的组合物，特别是非小细胞肺癌（NSCLC）
公开(公告)号：US20130202645A1
公开(公告)日：2013-08-08
申请号：US13750664
申请日：2013-01-25
申请人： CUREVAC GMBH
发明人： Marijke Barner , Jochen Probst , Thomas Lander , Ingmar Hoerr
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/53 , A61K2039/57 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
摘要翻译：本发明涉及包含至少一种编码至少两种（优选不同的）抗原的RNA，优选mRNA的活性（免疫刺激）组合物，其能够在哺乳动物中引发（适应性的）免疫应答。本发明还涉及包含所述活性（免疫刺激）组合物的疫苗，以及所述活性（免疫刺激性）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的用途治疗肺癌，特别是非小细胞肺癌（NSCLC），优选选自三种主要亚型鳞状细胞肺癌，腺癌和大细胞肺癌，或与其相关的疾病。最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。

59. 发明申请

US20130195867A1 RNA-CODED ANTIBODY 审中-公开
标题翻译： RNA编码抗体
公开(公告)号：US20130195867A1
公开(公告)日：2013-08-01
申请号：US13709897
申请日：2012-12-10
申请人： CureVac GmbH
发明人： Ingmar HOERR , Jochen Probst , Steve Pascolo
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： C07K16/1027 , A61K9/0019 , A61K39/395 , A61K39/39558 , A61K39/40 , A61K39/42 , A61K48/00 , A61K48/005 , A61K48/0066 , A61K48/0075 , A61K2039/505 , A61K2039/51 , A61K2039/53 , C07K16/1018 , C07K16/2803 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/3046 , C07K16/3061 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , Y02A50/388 , Y02A50/41 , Y02A50/412 , Y02A50/487
摘要： The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes and in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.
摘要翻译：本申请描述了抗体编码，未修饰或修饰的RNA及其用于表达该抗体的用途，用于制备药物组合物，特别是被动疫苗，用于治疗肿瘤和癌症疾病，心血管疾病，传染病，自身免疫疾病，病毒性疾病和单一疾病，例如也在基因治疗。本发明进一步描述和体外转录方法，使用根据本发明的RNA和体内方法来表达该抗体的体外方法。

60. 发明申请

WO2015101414A3 ARTIFICIAL NUCLEIC ACID MOLECULES 审中-公开
标题翻译：人工核酸分子
公开(公告)号：WO2015101414A3
公开(公告)日：2015-10-08
申请号：PCT/EP2014003480
申请日：2014-12-30
申请人： CUREVAC GMBH
发明人： THESS ANDREAS
IPC分类号： C12N15/67 , C12N15/85
CPC分类号： C12N15/85 , C12N15/67
摘要： The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-untranslated region element (3'-UTR) element comprising a nucleic acid sequence which is derived from the 3'-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3'-UTR element comprising a nucleic acid sequence which is derived from the 3'-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3'-UTR element.
摘要翻译：本发明涉及包含至少一个可读框和至少一个3'非翻译区元件（3'-UTR）元件的人工核酸分子，所述元件包含衍生自核糖体的3'-UTR的核酸序列蛋白质基因。本发明还涉及这种人造核酸分子在基因治疗和/或基因疫苗接种中的用途。此外，本发明涉及包含衍生自核糖体蛋白基因的3'-UTR的核酸序列的3'-UTR元件用于增强，稳定和/或延长来自核酸序列的蛋白质表达的用途，所述核酸序列包含这种3'-UTR元件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式